NBTF Introduces Neuroscience Nurse Consultations

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

OAKLAND, California-The National Brain Tumor Foundation (NBTF) has announced its new cancer online resource and toll-free telephone number. Patients and family members who have detailed medical questions regarding brain tumors can contact a neuroscience nurse for a free consultation.

OAKLAND, California—The National Brain Tumor Foundation (NBTF) has announced its new cancer online resource and toll-free telephone number. Patients and family members who have detailed medical questions regarding brain tumors can contact a neuroscience nurse for a free consultation.

“Our service is providing patients with the information to understand their treatment options,” said Mary Lovely, RN, PhD, of the NBTF. The neuroscience nurses are experienced interviewers with advanced knowledge of the diseases and a great deal of sensitivity to patient needs, she added.

The Patient Information Line, 1-800-934-CURE, provides current disease-related information on tumor types, treatment, and coping. Information specialists are available to speak with callers Monday through Friday from 9 am to 5 pm Pacific Standard Time.

Callers may also use the automated response system to order free materials on brain tumors and obtain information about the foundation and its programs or leave a recorded message. All messages are returned the next business day.

Instant access to the foundation’s resources is available on its website, located at www.braintumor.org.

The site also includes stories about other brain tumor survivors, a special pediatric page, and an illustrated guide to the brain.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.